miRagen Therapeutics to Participate in Four Investor Conferences in November
Nov 07, 2017 21:07 pm UTC| Business
BOULDER, Colo., Nov. 07, 2017 -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S....
Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results
Nov 07, 2017 21:07 pm UTC| Business
Total Revenues of $190.2 Million Up 7 PercentGAAP Diluted EPS of $1.15 and Adjusted EPS of $0.26 Up 13 PercentGeneSight® Demonstrates Statistical Significance for Response and Remission in Prospective Study SALT LAKE...
Nov 07, 2017 21:07 pm UTC| Business
COSTA MESA, Calif., Nov. 07, 2017 -- TTM Technologies, Inc. (Nasdaq:TTMI), a global leader in printed circuit board (PCB) manufacturing, will be exhibiting at the annual International Printed Circuit APEX South China...
SCI and Dignity Memorial® Join National Infantry Museum to Honor Veterans
Nov 07, 2017 21:07 pm UTC| Business
HOUSTON, Nov. 07, 2017 -- Service Corporation International (NYSE:SCI), North America’s largest provider of funeral and cemetery services, and its brand, Dignity Memorial, have joined the National Infantry Museum this...
Bellicum Reports Third Quarter 2017 Financial Results
Nov 07, 2017 21:07 pm UTC| Business
HOUSTON, Nov. 07, 2017 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial...
Cavco Industries Reports Fiscal 2018 Second Quarter Results
Nov 07, 2017 21:07 pm UTC| Business
PHOENIX, Nov. 07, 2017 -- Cavco Industries, Inc. (NASDAQ:CVCO) today announced financial results for the second fiscal quarter ended September 30, 2017. On April 3, 2017, the Company completed the acquisition of...
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
Nov 07, 2017 21:07 pm UTC| Business
AUSTIN, Texas, Nov. 07, 2017 -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases...